Copyright Reports & Markets. All rights reserved.

Global Pulmonary Hypertension Drug Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Pulmonary Hypertension Drug

      • 1.1 Definition of Pulmonary Hypertension Drug
      • 1.2 Pulmonary Hypertension Drug Segment by Type
        • 1.2.1 Global Pulmonary Hypertension Drug Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Prostacyclin and Prostacyclin Analogs
        • 1.2.3 Endothelin Receptor Antagonists
        • 1.2.4 Phosphodiesterase-5 Inhibitors
        • 1.2.5 Soluble Guanylate Cyclase Stimulators
      • 1.3 Pulmonary Hypertension Drug Segment by Applications
        • 1.3.1 Global Pulmonary Hypertension Drug Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Early-stage Drug Candidates (Phase I & Phase II)
        • 1.3.3 Late-stage Drug Candidates (Phase III & Registration Phase)
      • 1.4 Global Pulmonary Hypertension Drug Overall Market
        • 1.4.1 Global Pulmonary Hypertension Drug Revenue (2014-2025)
        • 1.4.2 Global Pulmonary Hypertension Drug Production (2014-2025)
        • 1.4.3 North America Pulmonary Hypertension Drug Status and Prospect (2014-2025)
        • 1.4.4 Europe Pulmonary Hypertension Drug Status and Prospect (2014-2025)
        • 1.4.5 China Pulmonary Hypertension Drug Status and Prospect (2014-2025)
        • 1.4.6 Japan Pulmonary Hypertension Drug Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Pulmonary Hypertension Drug Status and Prospect (2014-2025)
        • 1.4.8 India Pulmonary Hypertension Drug Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Pulmonary Hypertension Drug
      • 2.3 Manufacturing Process Analysis of Pulmonary Hypertension Drug
      • 2.4 Industry Chain Structure of Pulmonary Hypertension Drug

      3 Development and Manufacturing Plants Analysis of Pulmonary Hypertension Drug

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Pulmonary Hypertension Drug Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Pulmonary Hypertension Drug
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Pulmonary Hypertension Drug Production and Capacity Analysis
      • 4.2 Pulmonary Hypertension Drug Revenue Analysis
      • 4.3 Pulmonary Hypertension Drug Price Analysis
      • 4.4 Market Concentration Degree

      5 Pulmonary Hypertension Drug Regional Market Analysis

      • 5.1 Pulmonary Hypertension Drug Production by Regions
        • 5.1.1 Global Pulmonary Hypertension Drug Production by Regions
        • 5.1.2 Global Pulmonary Hypertension Drug Revenue by Regions
      • 5.2 Pulmonary Hypertension Drug Consumption by Regions
      • 5.3 North America Pulmonary Hypertension Drug Market Analysis
        • 5.3.1 North America Pulmonary Hypertension Drug Production
        • 5.3.2 North America Pulmonary Hypertension Drug Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Pulmonary Hypertension Drug Import and Export
      • 5.4 Europe Pulmonary Hypertension Drug Market Analysis
        • 5.4.1 Europe Pulmonary Hypertension Drug Production
        • 5.4.2 Europe Pulmonary Hypertension Drug Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Pulmonary Hypertension Drug Import and Export
      • 5.5 China Pulmonary Hypertension Drug Market Analysis
        • 5.5.1 China Pulmonary Hypertension Drug Production
        • 5.5.2 China Pulmonary Hypertension Drug Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Pulmonary Hypertension Drug Import and Export
      • 5.6 Japan Pulmonary Hypertension Drug Market Analysis
        • 5.6.1 Japan Pulmonary Hypertension Drug Production
        • 5.6.2 Japan Pulmonary Hypertension Drug Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Pulmonary Hypertension Drug Import and Export
      • 5.7 Southeast Asia Pulmonary Hypertension Drug Market Analysis
        • 5.7.1 Southeast Asia Pulmonary Hypertension Drug Production
        • 5.7.2 Southeast Asia Pulmonary Hypertension Drug Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Pulmonary Hypertension Drug Import and Export
      • 5.8 India Pulmonary Hypertension Drug Market Analysis
        • 5.8.1 India Pulmonary Hypertension Drug Production
        • 5.8.2 India Pulmonary Hypertension Drug Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Pulmonary Hypertension Drug Import and Export

      6 Pulmonary Hypertension Drug Segment Market Analysis (by Type)

      • 6.1 Global Pulmonary Hypertension Drug Production by Type
      • 6.2 Global Pulmonary Hypertension Drug Revenue by Type
      • 6.3 Pulmonary Hypertension Drug Price by Type

      7 Pulmonary Hypertension Drug Segment Market Analysis (by Application)

      • 7.1 Global Pulmonary Hypertension Drug Consumption by Application
      • 7.2 Global Pulmonary Hypertension Drug Consumption Market Share by Application (2014-2019)

      8 Pulmonary Hypertension Drug Major Manufacturers Analysis

      • 8.1 GlaxoSmithKline plc
        • 8.1.1 GlaxoSmithKline plc Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.1.2 GlaxoSmithKline plc Product Introduction, Application and Specification
        • 8.1.3 GlaxoSmithKline plc Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Novartis AG
        • 8.2.1 Novartis AG Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.2.2 Novartis AG Product Introduction, Application and Specification
        • 8.2.3 Novartis AG Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Merck & Co., Inc.
        • 8.3.1 Merck & Co., Inc. Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.3.2 Merck & Co., Inc. Product Introduction, Application and Specification
        • 8.3.3 Merck & Co., Inc. Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Abbott Laboratories
        • 8.4.1 Abbott Laboratories Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.4.2 Abbott Laboratories Product Introduction, Application and Specification
        • 8.4.3 Abbott Laboratories Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Boehringer Ingelheim GmbH
        • 8.5.1 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.5.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
        • 8.5.3 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 AstraZeneca plc
        • 8.6.1 AstraZeneca plc Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.6.2 AstraZeneca plc Product Introduction, Application and Specification
        • 8.6.3 AstraZeneca plc Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 F. Hoffmann-La Roche AG
        • 8.7.1 F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.7.2 F. Hoffmann-La Roche AG Product Introduction, Application and Specification
        • 8.7.3 F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Teva Pharmaceutical Industries Ltd.
        • 8.8.1 Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.8.2 Teva Pharmaceutical Industries Ltd. Product Introduction, Application and Specification
        • 8.8.3 Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Vectura Group plc
        • 8.9.1 Vectura Group plc Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.9.2 Vectura Group plc Product Introduction, Application and Specification
        • 8.9.3 Vectura Group plc Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Pfizer Inc.
        • 8.10.1 Pfizer Inc. Pulmonary Hypertension Drug Production Sites and Area Served
        • 8.10.2 Pfizer Inc. Product Introduction, Application and Specification
        • 8.10.3 Pfizer Inc. Pulmonary Hypertension Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served

      9 Development Trend of Analysis of Pulmonary Hypertension Drug Market

      • 9.1 Global Pulmonary Hypertension Drug Market Trend Analysis
        • 9.1.1 Global Pulmonary Hypertension Drug Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Pulmonary Hypertension Drug Regional Market Trend
        • 9.2.1 North America Pulmonary Hypertension Drug Forecast 2019-2025
        • 9.2.2 Europe Pulmonary Hypertension Drug Forecast 2019-2025
        • 9.2.3 China Pulmonary Hypertension Drug Forecast 2019-2025
        • 9.2.4 Japan Pulmonary Hypertension Drug Forecast 2019-2025
        • 9.2.5 Southeast Asia Pulmonary Hypertension Drug Forecast 2019-2025
        • 9.2.6 India Pulmonary Hypertension Drug Forecast 2019-2025
      • 9.3 Pulmonary Hypertension Drug Market Trend (Product Type)
      • 9.4 Pulmonary Hypertension Drug Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Pulmonary Hypertension Drug Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.

        The global Pulmonary Hypertension Drug market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Pulmonary Hypertension Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Hypertension Drug market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Hypertension Drug in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Pulmonary Hypertension Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        GlaxoSmithKline plc
        Novartis AG
        Merck & Co., Inc.
        Abbott Laboratories
        Boehringer Ingelheim GmbH
        AstraZeneca plc
        F. Hoffmann-La Roche AG
        Teva Pharmaceutical Industries Ltd.
        Vectura Group plc
        Pfizer Inc.

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Prostacyclin and Prostacyclin Analogs
        Endothelin Receptor Antagonists
        Phosphodiesterase-5 Inhibitors
        Soluble Guanylate Cyclase Stimulators

        Segment by Application
        Early-stage Drug Candidates (Phase I & Phase II)
        Late-stage Drug Candidates (Phase III & Registration Phase)

        Buy now